Measurement of C-reactive protein, another hot topic, is rated class III (no benefit) in asymptomatic adults who are defined as high-risk by the Adult Treatment Panel III standard of a greater than 20% 10-year risk. Similarly, CRP is class III in low-risk men younger than age 50 and in low-risk women younger than age 60.
However, CRP gets a class IIa recommendation as a guide to deciding on statin therapy in men aged 50 or older and in women aged 60 and older with an LDL cholesterol level of less than 130 mg/dL. It gets a class IIb recommendation in asymptomatic men and women aged 50 and 60 years, respectively, or younger.
The full 54-page guideline was released online in Circulation during the conference, and it is available at http://circ.ahajournals.org/cgi/reprint/CIR.0b013e3182051b4cv1
Dr. Smith declared having no relevant financial interests. Dr. Greenland disclosed serving as a consultant to Pfizer, General Electric, and Toshiba.
'Genetic testing is a sexy area right now, but we didn't see it as being ready or as having shown added value.'
Source DR. SMITH